SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of abrupt layoffs in India and the Philippines, attributed to a scaled-down business assignment, have fueled concern that Innodata may have lost or reduced work from a major customer; the company has not clarified the situation. Traders are divided between viewing the sharp selloff as an overreaction or fearing a revenue hit, with many looking to the upcoming earnings update for answers.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

A sharp rebound and technical breakout have drawn attention, with traders citing a rotation into housing-related stocks and easing-yield hopes. Bulls see room for the move to continue, while skeptics point to high borrowing costs and weak housing demand.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotles Q3 results sparked a rally as comparable-sales growth exceeded expectations, though earnings missed and margins weakened. Traders are debating whether improving sales momentum can outweigh cost pressures and softer consumer trends, with some viewing the move as a recovery signal and others remaining cautious.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anticipation of QUILT-2.005 Phase 3 topline results for ANKTIVA plus BCG in first-line, BCG-nave bladder cancer dominates discussion, with traders watching for evidence that could support a broader label and the planned supplemental filing. Bulls see the readout and quarterly sales update as potential validation of the growth story, while skeptics highlight execution and competition; some attribute a recent bounce to Jim Cramers favorable remarks, though others dismiss that as temporary.

World Liberty Financial (WLFI) is a cryptocurrency launched in 2025and operates on the Ethereum platform. World Liberty Financial has a current supply of 100,000,000,000 with 31,779,991,497 in circulation. The last known price of World Liberty Financial is 0.05007445 USD and is up 0.02 over the last 24 hours. It is currently trading on 491 active market(s) with $20,910,403.62 traded over the last 24 hours. More information can be found at https://www.worldlibertyfinancial.com/.

WorldFinancial

WLFI is drawing attention over its weak, range-bound trading and speculation that a bank charter and future USD1 utility could lift the Trump-linked token. Bulls cite those potential catalysts and a limited tradable supply, while skeptics argue the token has lagged the broader crypto market and question its value amid concerns about the project and Trump familys crypto earnings.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs Q3 results sparked an earnings-driven rally, with traders pointing to improved profitability and cash generation despite declining revenue and continued BetterHelp weakness. Bulls see signs of a turnaround and potential short squeeze, while skeptics question whether the gains are justified before revenue growth returns.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has intensified concerns about competition for Precigens PAPZIMEOS. Traders debate whether the rivals potential to reduce surgeries will challenge PAPZIMEOS, while bulls point to Precigens first-mover commercial lead and full approval versus questions about Inovios accelerated-approval requirements and launch capacity.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

A sharp UVXY rally has focused attention on volatility trading, with some traders betting on further VIX-related gains while others are shorting the fund and expecting volatility to fade. The debate also reflects frustration that UVXY tracks short-term VIX futures rather than spot VIX, so its moves may differ from traders expectations.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas post-earnings rally is the main focus: traders point to strong revenue and unit growth and the SECs decision not to pursue enforcement, while critics emphasize the EPS miss, margin pressure, reduced guidance, and insider share monetization. Bulls cite short-squeeze potential; bears question the valuation and durability of the gains.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circles CFO plans to step down, while co-founder Sean Neville has also resigned from the board, drawing attention to leadership changes as shares fall. Traders debate whether the departures signal deeper concerns or an orderly transition; Circle has described them as amicable and said the CFO will remain through the handover.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales

Exelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.

Exelixis Q3 2026 Earnings Call Transcript

Exelixis (NASDAQ:EXEL) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.Benzinga APIs provide real-time access to earnings callread more...

Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of +5.62% and +0.86%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. Exelixis continued to execute across all of our key...

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

Key PointsRegulators in the U.S. extended the review period for Exelixis' request to approve a new cancer drug...

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a...

$EXEL Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.94 up 20.51% YoY
• Reported revenue of $658.7M up 10.20% YoY
• Exelixis FY2026 guidance maintains total revenues of $2.5B - $2.55B and net product revenues of $2.3B - $2.35B; effective tax rate is 16% - 18%, versus 21% - 23% previously.

Stocktwits

Exelixis Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.94 up 20.51% YoY
• Reported revenue of $658.7M up 10.20% YoY
• Exelixis FY2026 guidance maintains total revenues of $2.5B - $2.55B and net product revenues of $2.3B - $2.35B; effective tax rate is 16% - 18%, versus 21% - 23% previously.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $0.94 up 20.51% YoY
• Reported revenue of $658.7M up 10.20% YoY
• Exelixis FY2026 guidance maintains total revenues of $2.5B - $2.55B and net product revenues of $2.3B - $2.35B; effective tax rate is 16% - 18%, versus 21% - 23% previously.

Exelixis CRC NDA review was extended three months, with a non-statistically significant OS trend in the NLM subpopulation; R&D and SG&A expenses rose, and generic competition remains a stated risk.

Exelixis Q3 cabozantinib product revenues increased with higher sales volume and average net selling price; STELLAR-303 met an overall-survival endpoint and zanzalintinib studies were initiated and enrolling.

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The FDA will now decide on Exelixis’s new application by March 3, 2027.</li><li>A March decision would push a possible U.S. launch out of this year and into 2027.&nbsp;</li><li>William Blair said it was “surprised” by the three-month delay but still sees a low chance of an outright rejection, because the combination showed a survival benefit in the main study group.</li></ul>Shares of Exelixis (EXEL) fell 2% on Friday after the company said U.S. regulators added three months to the review of its next cancer drug, but William Blair still sees a low chance of an outright rejection.The Food and Drug Administration told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread, the company said in a filing with the Securities and Exchange Commission on Friday. The new target decision date is March 3, 2027. The old date was December 3, 2026. A March decision would push a possible U.S. launch out of this year and into 2027.<h2 class="st-heading-2">Why The Clock Moved</h2>The FDA asked for more information and Exelixis sent updated safety and efficacy results, the company said. The agency treated that package as a major change to the application and extended its review period.The FDA accepted Exelixis’s application in February for adults with metastatic colorectal cancer who had already received standard chemotherapy. Patients whose tumors lacked a common RAS mutation also had to have tried a separate targeted drug first.The filing rests on STELLAR-303, a late-stage study that tested Exelixis’s oral drug with Tecentriq against Bayer’s Stivarga. In the full study population, patients on the combination lived longer.Doubt remains because a second, pre-set test missed its mark. In June, Exelixis said patients without active liver tumors showed a similar trend but not a statistically clear survival win. Investors have worried the mixed result could slow the review, narrow the label, or invite extra questions. Friday’s filing did not say the new data requested by the FDA came from that subgroup.<h2 class="st-heading-2">Analyst Shrugs Off Rejection Risk</h2>William Blair said it was “surprised” by the three-month delay but still sees a low chance of an outright rejection, because the combination showed a survival benefit in the main study group. The firm said the extra wait should not materially cut the drug’s long-term sales, though the stock may swing more in the near term. It kept an ‘Outperform’ rating.Zanzalintinib is Exelixis’s bid for a second commercial franchise after Cabometyx, the cabozantinib tablet that still accounts for nearly all of the company’s product sales. Cabometyx is approved for kidney, liver, and neuroendocrine cancers and generated about $2.12 billion in U.S. net product revenue in 2025.<h2 class="st-heading-2">How Did EXEL Retail Traders React?</h2>On Stocktwits, retail sentiment around EXEL stock fell from ‘neutral’ to ‘bearish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.“A delay is a delay nothing else,” a Stocktwits user said.<stembedurl>https://stocktwits.com/svb64/message/664065334</stembedurl><a href="https://stocktwits.com/symbol/EXEL">EXEL stock</a> has gained 28% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/axsm-jumps-6-as-mizuho-calls-auvelity-s-alzheimer-s-launch-a-strong-start/cZtXr0oRBbQ">AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Exelixis Inc company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread. 

iShares Core S&P Mid-Cap ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$69.39
Prev Close	$66.20
Open	$68.28
Dividend Yield	0.00%
50-Day Moving Average	$59.39
Beta	0.50
Avg. Volume	2.22M
PE Ratio	20.77

52-Week High	$72.10
52-Week Low	$36.00
Market Capitalization	$16.93B
EPS (Annual)	$2.78
Price to Book	9.26
Revenue Per Employee	$2.15M

Feed

News

Sentiment

Earnings

Fundamentals

Info

EXEL Fundamentals